AbCellera Biologics Inc (ABCL)
3.72
+0.09
(+2.48%)
USD |
NASDAQ |
Apr 26, 09:45
AbCellera Biologics Cash from Operations (TTM): -43.88M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -43.88M |
| September 30, 2023 | 6.646M |
| June 30, 2023 | -120.03M |
| March 31, 2023 | 133.08M |
| December 31, 2022 | 277.36M |
| September 30, 2022 | 229.74M |
| June 30, 2022 | 350.59M |
| Date | Value |
|---|---|
| March 31, 2022 | 235.26M |
| December 31, 2021 | 244.58M |
| September 30, 2021 | 262.57M |
| June 30, 2021 | 264.70M |
| March 31, 2021 | 133.00M |
| December 31, 2020 | 22.69M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-120.03M
Minimum
Jun 2023
350.59M
Maximum
Jun 2022
153.56M
Average
229.74M
Median
Sep 2022
Cash from Operations (TTM) Benchmarks
| Acasti Pharma Inc | -13.57M |
| Aurinia Pharmaceuticals Inc | -33.46M |
| Edesa Biotech Inc | -6.252M |
| Lexaria Bioscience Corp | -5.209M |
| InMed Pharmaceuticals Inc | -6.337M |